Reata Pharma (RETA) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development Programs
February 28, 2022 6:45 AM ESTInitiated Rolling Submission of NDA for Omaveloxolone for Treatment of Patients with Friedreich's Ataxia; Actively Preparing for Commercial Launch
Updated Cash Guidance - Sufficient to Fund Operations Through End of 2024
Conference Call with Management on February 28, 2022, at 8:30 A.M. ET
PLANO, Texas--(BUSINESS WIRE)-- Reata Pharmaceuticals, Inc. (Nasdaq:... More
